# Operational Feasibility of Appropriate Radical Cure of Plasmodium Vivax With Tafenoquine or Primaquine After Quantitative G6PD Testing in Brazil

> **NCT05096702** · — · UNKNOWN · sponsor: **Fundação de Medicina Tropical Dr. Heitor Vieira Dourado** · enrollment: 16000 (actual)

## Conditions studied

- Malaria, Vivax
- G6PD Deficiency

## Interventions

- **DRUG:** Tafenoquine
- **DRUG:** Primaquine
- **DRUG:** Primaquine

## Key facts

- **NCT ID:** NCT05096702
- **Lead sponsor:** Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-09
- **Primary completion:** 2022-08-30
- **Final completion:** 2023-09-09
- **Target enrollment:** 16000 (ACTUAL)
- **Last updated:** 2023-06-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05096702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05096702, "Operational Feasibility of Appropriate Radical Cure of Plasmodium Vivax With Tafenoquine or Primaquine After Quantitative G6PD Testing in Brazil". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05096702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*